Palisade Bio, Inc.: financial statements

PALINASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.84

November 20, 2026Market cap $151M

What Ploutos Investor adds for Palisade Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from 2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 26% since Nov 10, 2026, when the 10-Q these figures come from was filed ($1.13 then, $0.84 on Nov 20, 2026). The figures date from before that move.10-Q

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

Line202320242025Average a year
Revenue $300.0K$0$0
Operating income -$13M-$15M-$18M
Net income -$12M-$14M-$17M
Earnings per share -$27.01-$10.19-$0.30
Earnings per share, basic -$27.01-$10.19-$0.30
Margins
Operating margin -4,356.7%––
Net margin -4,100.0%––

Financial statements

PALI's revenue, profits and cash flows from 2010 to 2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

0.0% Effective tax rate

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

+12.0 pts

Adjustment to Deferred Tax Balances

-26.2 pts

Non-deductible expenses

-3.7 pts

Executive pay deduction limit

-2.6 pts

Not itemized in the filing

+0.1 pts

Smaller lines (2)

-0.6 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate PALI paid on its profit, from 2011 to 2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Palisade Bio's filings show?

These are Palisade Bio's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about PALI's financials

Didn't find what you were looking for?

Ask us
How much revenue did PALI have in 2025?

Palisade Bio had revenue of $0 and net income of -$17M in fiscal 2025, a net margin of .

How much debt does PALI have?

On December 31, 2025 Palisade Bio had total assets of $134M, debt of – and shareholders' equity of $129M.

Where are the figures from?

From Palisade Bio, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.